Microbiology, Tuberculosis & Pulmonary Infections
Please plan to submit a new MTPI project!
Our MPTI membership includes many opinion leaders in pulmonary infection, diagnostics and treatment. An important role of our group is to generate reference documents such as guidelines and position papers that exploit this resource of pulmonary infection scholars. Please consider what topics you would like to see addressed by MTPI in advance of the call for projects in July 2015. We need new authors to apply for these awards.
Richard G. Wunderink, MD
Welcome to the website of the Assembly for Microbiology, Tuberculosis, and Pulmonary Infections (MTPI). The MTPI Assembly represents clinicians, scientists, and public health practitioners from across the globe. Our assembly focuses on all aspects of pulmonary infections and host defense. At present, we have 817 primary members and 2,003 secondary members, with about one-third of our membership from outside of North America.
We are one of the most productive and visible Assemblies within ATS. Our statements and guidelines are highly cited and have helped to establish and improve practice in the diagnosis and treatment of a wide variety of pulmonary infections, including community-acquired pneumonia, hospital-acquired/ventilator-associated pneumonia, and pneumonia in the immunocompromised host; tuberculosis and non-tuberculous mycobacterial infections; fungal infections; and bronchiectasis. Our symposia and mini-symposia at the ATS Annual Meeting continue to provide some of the best opportunities for clinicians and scientists to be kept abreast of recent advances in the diagnosis, treatment, and control of respiratory infections. Thematic poster sessions allow interaction with some of the cutting edge research in these areas.
This is an exciting yet challenging time to be involved with pulmonary infections. The availability of improving diagnostics, new and re-purposed antibiotics for both mycobacterial and bacterial pneumonia, and emerging data regarding the lung microbiome and its role in pulmonary disease has stimulated great interest. Conversely, the increase in multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of bacteria and tuberculosis pose a threat to the dramatic improvements in health resulting from effective antibiotics. Pandemic influenza, SARS and MERS have also increased awareness of the role of serious viral respiratory tract infections and the lack of effective anti-viral treatment for both new or previously known respiratory viruses.
So if the challenge of clinical management of respiratory infections, understanding the pathophysiology and epidemiology, or developing new treatment paradigms, we encourage you to join us in the MTPI Assembly. Our Assembly particularly encourages participation by junior members, including fellows, through a variety of programs in order to meet the future challenges in pulmonary infections. For more information about the Assembly contact us at firstname.lastname@example.org.
Richard G. Wunderink, MD, Assembly Chair
David M. Lewinsohn, MD, PhD, Immediate Past Assembly Chair
Kevin P. Fennelly, MD, Program Chair
Joseph M. Keane, MD, Planning Chair
Scott Evans, MD, Web Director
Nathan Dean, MD , Nominating Chair
|Download the ATS Assembly on MTPI brochure|